Does nephrotoxicity exist in pediatric epileptic patients on valproate or carbamazepine therapy?

Area of Science:

• Pediatric Nephrology
• Clinical Pharmacology

Background:

• Epilepsy is a common neurological disorder in children.
• Valproate and carbamazepine are frequently prescribed antiepileptic drugs.
• Potential renal side effects of these medications require investigation.

Purpose of the Study:

• To evaluate the impact of valproate and carbamazepine on renal glomerular and tubular functions in children with new-onset epilepsy.
• To compare renal function markers between patients treated with valproate, carbamazepine, and healthy controls.

Main Methods:

• Prospective study involving 54 children with new-onset epilepsy and 26 healthy controls.
• Measurement of serum creatinine, cystatin C, and urinary N-acetyl-β-d-glucosaminidase (NAG) excretion.
• Estimation of glomerular filtration rate (GFR) and calculation of urinary NAG/creatinine ratio.

Main Results:

• No significant differences in serum creatinine or cystatin C between patients and controls.
• Glomerular filtration rate (GFR) was higher in both valproate and carbamazepine groups compared to controls, suggesting glomerular hyperfiltration.
• Urinary NAG/creatinine levels were significantly elevated only in the valproate group, indicating tubular dysfunction.

Conclusions:

• Both valproate and carbamazepine may induce glomerular hyperfiltration and potential glomerular toxicity in pediatric epilepsy patients.
• Valproate demonstrates a specific adverse effect on renal tubular function, evidenced by increased urinary NAG excretion.
• Further monitoring of renal function is recommended for children treated with these antiepileptic drugs, particularly valproate.